Companies › Hemab ApS
4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Hematology, Other; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Sutacimig Bispecific antibody binding activated factor VII and TLT-1 on platelets | F7, TREML1 | Phase 2 | Congenital Factor VII Deficiency | Nov 2027 |
| HMB-003 | – | Phase 1 | Healthy Adult Participants | Apr 2027 |
| HMB-002 Von Willebrand factor (VWF) replacement or augmentation therapy | – | Phase 1 | Von Willebrand Disease (VWD) | Jul 2027 |
| HMB-001 Bispecific antibody bridging platelet glycoprotein receptors to promote platelet aggregati | – | Phase 1 | Glanzmann Thrombasthenia | Aug 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07798505 | HMB-003 | Phase 1 | Healthy Adult Participants | Other | Apr 2027 |
| NCT06754852 | HMB-002 | Phase 1 | Von Willebrand Disease (VWD) | Hematology | Jul 2027 |
| NCT06211634 | HMB-001 | Phase 1 | Glanzmann Thrombasthenia | Hematology | Aug 2027 |
| NCT07347249 | Sutacimig | Phase 2 | Congenital Factor VII Deficiency | Hematology | Nov 2027 |
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Jiangsu BioJeTay Biotechnology Shanghai RAAS Blood Products Agios Pharmaceuticals Imara Prothya Biosolutions
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.